Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F2F22D + DL001Z
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
F2F22D + DL001Z is an investigational mRNA-based influenza vaccine candidate developed by GSK in collaboration with CureVac. It is a specific formulation within the GSK4382276A multivalent vaccine program, which utilizes CureVac's second-generation mRNA backbone technology. The candidate consists of a specific mRNA construct (F2F22D) encapsulated in a lipid nanoparticle delivery system (DL001Z). It is designed to induce an immune response against hemagglutinin (HA) antigens from multiple influenza strains to provide protection against seasonal or pandemic influenza. F2F22D + DL001Z was evaluated in Phase 1/2 clinical trials (e.g., NCT05823974) to assess its safety, reactogenicity, and immunogenicity in healthy younger and older adults. In July 2024, GSK assumed full control of the development and commercialization of the program, which has since reported positive Phase 2 data and is progressing toward Phase 3 trials.
- Other names
- Flu mRNA vaccineGSK/CureVac influenza mRNA vaccineGSK4382276A candidateGSK-4382276A candidateGSK 4382276A candidate
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on F2F22D + DL001Z.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F2F22D + DL001Z.